FAMILIAL AMYLOID POLYNEUROPATHY (TTR-FAP): Genetics and Treatment
|
|
- Gregory Cameron
- 5 years ago
- Views:
Transcription
1 FAMILIAL AMYLOID POLYNEUROPATHY (TTR-FAP): Genetics and Treatment Michelle Mezei BSc (Pharm), MDCM, FRCPC Neuromuscular Diseases Unit, VGH Division of Neurology, UBC 1
2 Learning Objectives To become familiar with Familial Amyloid Polyneuropthy hattr (Hereditary Transthyretin Amyloidosis) To review novel treatment options in hattr
3 Disclosures Principle Investigator: Alnylam Apollo and Patisiran OLE trials Honoraria: Alnylam: speaker and symposium chair Pfizer: Advisory Board Chair and speaker Genzyme: speaker
4 Patient Case Study 2008: 48 year old female with bilateral burning foot pain, numbness, progresses within 6 months to knees, and hands (predominantly ulnar distribution) Mild distal weakness, Glove-stocking deficit, absent ankle jerks Sensory>motor PN of axonal type, mild active denervation Family Hx: father died age 42 after 3 yr hx of sporadic amyloidosis (renal and PN); Confirmed V71A TTR mutation 2009: Ambulation limited by pain and imbalance, using cane hydromorphone, pregabalin gabapentin, Diflunisal Nausea/vomiting: improved with domperidone
5 Patient Case Study 2010: Ambulation limited to ½ block; loss of knee jerks; increased arm numbness Hydromorphone, duloxetine 2011: Increasing distal leg weakness, occasional walker 2014: Left followed by right visual loss: vitreous amyloid, successful vitrectomy : Apollo trial Pain improves, minimal GI sxs, improved endurance
6 Patient Case Study : Patisiran Open Label Extension study (OLE) Improved strength hands, resumed painting Dictus brace, cane, wheelchair outside Numbness stable, no dysesthesias Decreased dose of hydromorphone, duloxitine Less autonomic, no further V/D/bloating, mild Nausea Normal Echo and EKG
7 What is amyloidosis? The amyloidoses are a group of diseases that result from the abnormal deposition of amyloid protein in various tissues of the body causing clinically relevant changes 1,2 Amyloidosis Localized amyloidosis Systemic amyloidosis Primary (AL) amyloidosis Secondary (AA) amyloidosis Senile systemic amyloidosis (wild-type) Transthyretin familial amyloid polyneuropathy Affected organs: Kidney Heart Liver GI system Nervous system Affected organs: Kidneys Liver Spleen Affected organ: Heart Affected organs: Nervous system Heart 1. Kumar P, Clark M. Diabetes mellitus and other disorders of metabolism. In: Kumar P, Clark M, Kumar and Clark s Clinical Medicine; 7th Edition: Saunders, Elsevier, Merlini G et al. J Intern Med 2004;255:
8 Different precursor protein, same end result Apolipoprotein A1 Immunoglobulin light chain Lysozyme Transthyretin Β2 microglobulin Serum amyloid A Gelsolin Leukocyte chemotactic factor 2 (LECT2) Fibrinogen α- chain
9 Transthyretin is a transport protein of thyroxine and retinol-binding protein (RBP)/vitamin A 1 3 BLOOD VESSEL The transthyretin tetramer transports retinol through the RBP, vitamin A complex and thyroxine Less than 1% of transthyretin tetramers transport thyroxine in human serum The bulk of thyroxine is carried by thyroxine-binding globulin and albumin The majority of circulating transthyretin is not bound 3 TTR RBP Thyroxine 1. Benson MD, Kincaid JC. Muscle Nerve 2007;36: Sekijima Y et al. Curr Pharm Des 2008;14: Hou X et al. FEBS J 2007;274:
10
11 Genetic mutations lead to variant forms of transthyretin Benson MD, Kincaid JC. Muscle Nerve 2007;36: Roberts JR et al. Amyloidosis: Transthyretin-Related. Medscape, Accessed August Zeldenrust SR. In: Gertz MA et al. eds. Amyloidosis: Diagnosis and Treatment (Contemporary Hematology). Totowa: Humana Press, Planté-Bordeneuve V et al. Neurology 2007;69:
12
13 Autosomal dominant inheritance 1 4 TTR-FAP is an autosomal dominant disease Gene on chromosome 18 Affected parent has a 50% chance passing on mutated gene to their offspring Variable penetrance Affected individuals Unaffected individuals Square = male; Circle = female 1. Merlini G et al. J Intern Med 2004;255: Falk RH et al. N Engl J Med 1997;337: Stedman s Medical Dictionary. (27 th ed.) Philadelphia: Lippinocott Williams & Wilkins. 4. Benson MD, Kincaid JC. Muscle Nerve 2007;36:
14 hattr Genotype - Phenotype Genotypic-Phenotypic Correlation Late onset G47A A34T S50A A36P T49A P64L G89G V30M V41L S23A H88A C10A P33L Early onset V30M Neurologic Phenotype T60A L111M I68L V122I Cardiac 1. Based on Rapezzi et al. Eur Heart J 2013;34:520 8; 2. Coelho et al. Curr Med Res Opin 2013;29:63 76
15 Toxic amyloidogenic intermediates and amyloid deposits in peripheral and autonomic nerves 1,2 Amyloid PERIPHERAL NERVE BUNDLE Congo red-stained section of posterior tibial nerve from a patient with transthyretin amyloidosis shows hallmark green color under polarized light 2 1. Benson MD, Kincaid JC. Muscle Nerve 2007;36: Sousa MM et al. Am J Pathol 2001;159: Image courtesy M. Benson, Indiana University School of Medicine
16 Conceicao et al. J Peripher Nerv Syst 2016;21:5 9
17 Signs and Symptoms: Consider hattr Progressive, painful, predominantly small diameter PN Bilateral CTS Progressive length dependent sensory-motor PN, distal atrophy and weakness Autonomic sxs: Orthostatic hypotension Bladder symptoms: frequency, nocturia, erectile dysfunction Constipation and diarrhea, leading to unintentional weight loss Post-prandial nausea Systemic: Vitreous opacities: loss of vision Cardiac conduction defects, cardiomyopathy
18 Variable age of onset May manifest between 20 and 70 years of age 1,2 Disease course of late-onset hattr can be more severe and lead to disability more rapidly than early-onset disease 3 Progression to death within 5-15 years Don t always have Family Hx sporadic mutations family member with sporadic or primary amyloidosis Mean time to diagnosis can be up to 4 years after the onset of symptoms 4,5 1. Hou X et al. FEBS J 2007;274: Coelho T et al. CMRO 2013; 29: Adams D et al. Curr Opin Neurol 2012;25: Adams et al Amyloid 2012;19 Suppl 1: Plante-Bordeneuve et al. Neurology 2007;69:
19
20 99m Tc PYP Scanning Planar whole body scan ATTR CA AL CA With SPECT Falk et al. JACC 2016;68:1323
21 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved in EU and select other countries; b Available off label in some geographies; c Available as a generic medication, being studied by academic institutions ASO, antisense oligonucleotides; RNAi, RNA interference; TUDCA, tauroursodeoxycholic acid 1. Ando et al. Orphanet J Rare Dis 2013;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
22 Orthotopic Liver Transplantation (OLTX) Clinical Criteria: Age 60 yrs Dx duration 5 yrs PN restricted to LEs OR isolated AN No significant Renal OR Cardiac dysfunction Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; Takei et al., 1999; Adams et al., 2000 Poor Prognostic Facto BMI/nutritional status Severe PN Severe AN Urinary incontinence Marked postural hypote Fixed pulse rate
23 Domino Liver Transplantation
24
25 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved ASO, antisense in EU and oligonucleotides; select other countries; RNAi, RNA b Available interference; off label TUDCA, in some tauroursodeoxycholic geographies; c Available acid as a generic medication, being studied by academic institutions 1. Ando et al. Orphanet J Rare Dis ;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
26 Diflunisal - NSAID - Developed in mg and 500mg tablets
27 Diflunisal Take Home Points 2 year NIH sponsored Study Safe and Efficacious Reduced rate of progression of neurological impairment Reduced decline BMI Preserved quality of life Study suggests treatment benefit for FAP Off label use available in Canada Occasional lack of drug supply
28 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved in EU and select other countries; b Available off label in some geographies; c Available as a generic medication, being studied by academic institutions ASO, antisense oligonucleotides; RNAi, RNA interference; TUDCA, tauroursodeoxycholic acid 1. Ando et al. Orphanet J Rare Dis 2013;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
29
30 Tafamidis Clinical Development Program For TTR-FAP: Efficacy Data 18-mo, randomized double-blind, placebocontrolled study: Pivotal study in V30M patients with TTR-FAP 12-mo, open-label extension for Fx-005: Long-term safety and efficacy Study Fx-005 (n= 128) 1) Coelho T et al. Neurology 2012;79(8): ) Keohane D et al., Amyloid 2017;24(1):30-36 % NIS-LL responder (ITT): p= %NIS-LL responder (EE): p< ΔNIS-LL from baseline: p<0.05 1,2 ΔNQOL-DN from baseline (ITT): p= ΔNQOL-DN from baseline (EE): p< ΔNIS-LL+Σ3 from baseline: p< ΔNIS-LL+Σ7 from baseline: p< ΔmBMI from baseline (ITT): p< Study Fx-006 (n= 86) Coelho T et al. J Neurol. 2013;260(11): T-T: ΔNIS-LL (p=0.60); ΔTQOL (p=0.16) P-T: ΔNIS-LL (p<0.05); ΔTQOL (p<0.001) Earlier treatment start greater benefit Study Fx1A-201 (n= 21) Merlini G et al. J Cardiovasc. Trans. Res. 2013;6(6): mo, open-label, multicenter study: TTR stabilization in patients with non-v30m mutations TTR stabilized (6wk): 94.7% TTR stabilized (6mo): 100% TTR stabilized (12mo): 100% Open-label, ongoing, multicenter study: Long-term extension study (6+ yrs) for Fx- 006 and Fx1A-201 Study Fx1A-303 (Ongoing; n>93) Barroso F et al. Amyloid 2017; 24(3): Earlier treatment start greater benefit (continuous separation in ΔNIS-LL and ΔTQOL between T-T and P-T ) Prepared by Pfizer in response to an unsolicited request Not for further distribution
31 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved in EU and select other countries; b Available off label in some geographies; c Available as a generic medication, being studied by academic institutions ASO, antisense oligonucleotides; RNAi, RNA interference; TUDCA, tauroursodeoxycholic acid 1. Ando et al. Orphanet J Rare Dis 2013;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
32 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved in EU and select other countries; b Available off label in some geographies; c Available as a generic medication, being studied by academic institutions ASO, antisense oligonucleotides; RNAi, RNA interference; TUDCA, tauroursodeoxycholic acid 1. Ando et al. Orphanet J Rare Dis 2013;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
33 Investigational Disease-Modifying Therapeutics TTR-lowering Agents Antisense oligonucleotides (ASOs) m 7 G ASO ASO delivered as single strand; finds its target alone AAAA n RNA interference (RNAi) sirna RISC RISC Duplex associates with RISC Passenger strand is removed Guide strand leads RISC to target Blocking ribosomes or other factors steric block Recruiting protein factors (e.g. RNase H) Modulating splicing Serum TTR knockdown (mean maximum reduction 76%) m 7 G mrna cleavage (if perfectly complementary) RISC AAAA n Association-mediated repression (if partially mismatched) sirna, small Interfering RNA; RISC, RNA- induced silencing complex responsible for the silencing phenomenon known as RNA interference Watts & Corey. J Pathol 2012;226:365 79
34 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved in EU and select other countries; b Available off label in some geographies; c Available as a generic medication, being studied by academic institutions ASO, antisense oligonucleotides; RNAi, RNA interference; TUDCA, tauroursodeoxycholic acid 1. Ando et al. Orphanet J Rare Dis 2013;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
35 Inotersen: Antisense oligonucleotide IONIS-TTR Rx 15 month Phase 3 randomized (2:1), double blind, placebo-controlled international NEURO-TTR study 172 Stage 1 and 2 FAP patients 300mg sc weekly Highly statistically significant improvement in primary endpoints mnis+7 and Norfolk QOL Sustained and robust TTR AE: thrombocytopenia and renal dysfunction FDA/EMA: orphan drug designation PNS Meeting, July 10, 2017
36 Therapeutics Rate-limiting tetramer dissociation Monomer misfolding and aggregation leading to amyloid fibrils Suppression of TTR synthesis Liver transplantation 1 Investigational: Gene silencing ASOs: IONIS-TTR Rx 6 RNAi: Patisiran 7 ; ALN-TTRsc02 8 TTR stabilization Tafamidis 2,a Diflunisal 3,4,b Investigational: SOM0226 a Fibril degradation and reabsorption Investigational: Doxy + TUDCA 5,c Investigational Anti-amyloid mabs Anti-TTR mab 9 Anti-SAP mab 10 Management of disease Availability of disease-modifying therapies for hattr amyloidosis is limited Symptomatic relief is important for patients, particularly as disease progresses Genetic Counselling a Only approved in EU and select other countries; b Available off label in some geographies; c Available as a generic medication, being studied by academic institutions ASO, antisense oligonucleotides; RNAi, RNA interference; TUDCA, tauroursodeoxycholic acid 1. Ando et al. Orphanet J Rare Dis 2013;8:3; 2. Said et al. Nat Rev Drug Dis 2012;11:185 6; 3. Berk et al. JAMA 2013;310: ; 4. National Amyloidosis Centre. ATTR Amyloidosis url [accessed 18/12/2014]; 5. Ruberg & Berk. Circulation 2012;126: ; 6. Ackermann et al. Amyloid 2012;19(S1):43 4; 7. Coelho et al. N Engl J Med 2013;369:819 29; 8. Jadhav V, et al. Presentation at Oligonucleotide Therapeutics Society (OTS) meeting Higaki, et al. Amyloid 2016;23:86 97; 10. Richards, et al. N Engl J Med 2015;373:
37
38
39 Patisiran: Investigational RNAi Therapeutic for hattr Amyloidosis Therapeutic Hypothesis Lipid nanoparticle formulated RNAi, administered by IV infusion, targeting hepatic production of mutant and wild-type TTR Patisiran Therapeutic Hypothesis Production of mutant and wild type TTR Patisiran Unstable circulating TTR tetramers reduced Organ deposition of monomers, amyloid (β-pleated) fibril prevented, clearance promoted Neuropathy, cardiomyopathy stabilization or improvement 39
40 Patisiran Phase 3 APOLLO Study Results Study Enrollment D.Adams EU ATTR meeting, Nov patients with hattr amyloidosis with polyneuropathy from 44 sites in 19 countries enrolled between Dec 2013 and Jan % 2% 2% <1% <1% 1% <1% North America: 21% Western Europe: 44% 4% 4% 4% 19% USA 4% 4% Mexico 7% Germany 7% Japan 7% Spain 8% 16% France Taiwan 8% Rest of World: 36% 40 *North America: USA, CAN; Western Europe: DEU, ESP, FRA, GBR, ITA, NLD, PRT, SWE; Rest of world: Asia: JPN, KOR, TWN, Eastern Europe: BGR, CYP, TUR; Asia: JPN, KOR, TWN; Central & South America: MEX, ARG, BRA
41 Mean [± SEM] Serum TTR Knockdown, % Patisiran Phase 3 APOLLO Study Results Serum TTR Reduction 87.8% mean max serum TTR reduction from baseline for patisiran over 18 months Placebo (N=77) Patisiran (N=148) Weeks -100 TTR Change Change from baseline at 9 months Change from baseline at 18 months Placebo (N=77) Patisiran (N=148) Placebo (N=77) Patisiran (N=148) Mean (SEM) Serum TTR Knockdown 1.5% (4.47) 82.6% (1.36) 4.8% (3.38) 84.3% (1.48) 41
42 LS mean (SEM) change in mnis+7 from baseline Patisiran Phase 3 APOLLO Study Results mnis+7: Change from Baseline (2.60) (2.10) (11.0, 153.5) Difference at 18 mos (Pati PBO): p-value: Worse Better (8.0, 165.0) (1.50) (1.74) 42 MMRM, mixed-effects model repeated measures; mitt, modified intent to treat; Pati, patisiran; PBO, placebo; CFB, change from baseline mnis+7 reference range: points
43 Patisiran : Safety and Adverse Events 13 deaths in APOLLO study; no deaths considered related to study drug Similar frequency of deaths in patisiran and placebo Causes of death (e.g., cardiovascular, infection) consistent with natural history Similar % AE in Patisiran vs Placebo group Majority of AEs Were mild or moderate in severity Decreased over time Peripheral edema Infusion-related reactions (IRRs) No liver, hematological, or renal toxicity
44 Red-flag Symptom Cluster for hattr-pn Family history Early autonomic dysfunction Progressive symmetric sensory-motor neuropathy 1 of Gastrointestinal complaints Unexplained weight loss Cardiac hypertrophy, arrhythmias, ventricular blocks, or cardiomyopathy Renal abnormalities Vitreous opacities 44 Based on Conceicao et al. J Periph Nerv Syst 2016;21:5 9
45 Familial Amyloid Polyneuropathy (hattr Amyloidosis) SummaryanTreatment Rare and fatal neurodegenerative disease Mutation results in Tetramer destabilization, protein misfolding and amyloid deposits AD with variable penetrance Wide range age of onset Painful sensory > motor, autonomic peripheral neuropathy, CTS Often cardiac conduction/cardiomyopathy Need to think of it to dx and find it! Limited current Tx options available but novel ones on horizon
46 Acknowledgements Dr. Kristin Jack, UBC Dr. Margot Davis, UBC Dr. Diego Delgado, U of T Dr. Nowell Fine, U of C Pfizer Alnylam
47 The Differential Diagnosis Challenge for hattr- PN Symptoms may be common to other disorders, confounding diagnosis Patient phenotype Potential diagnoses Ataxia and foot numbness Motor involvement Upper limb neuropathy Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) ALS Motor polyradiculoneuropathy Carpal tunnel syndrome Idiopathic polyneuropathy Paraneoplastic neuropathy CIDP Motor neurone diseases Weakness in feet, ankles, legs Charcot Marie tooth disease Pain and tingling with alcohol abuse Alcoholic neuropathy Polyneuropathy with diabetes Diabetic neuropathy Polyneuropathy with evidence of amyloid deposition AL amyloidosis AA amyloidosis AA, amyloid A; AL, light-chain, ALS, amyotrophic lateral sclerosis Based on Adams et al. Curr Neurol Neurosci Rep 2014;14:435 & Adams et al. Curr Opin Neurol 2012;25:564 72
48 Surveillance/Other Considerations Multidisciplinary Approach Blood work Serial EDX Serial Cardiac Investigations (EKG, echo) Monitoring nutritional status Genetic Counseling Offer at-risk relatives molecular genetics testing Referrals
49 Inclusion Criteria: Age yrs Bx proven amyloid deposition and/or + TTR molecular genetics testing Assessed by Neurologist w proven Sensorimotor PN spending 50% time out of chair/bed Exclusion Criteria: Alternate cause for PN Survival 2 years Severe CHF Renal insufficiency Anticoagulation
50 1. Higaki et al. Amyloid 2016;23:86 97; 2. ClinicalTrials.gov: NCT Investigational Disease-Modifying Therapeutics Monoclonal Antibodies (mabs) mabs have been designed to bind to non-native, misfolded forms of TTR Promote clearance of non-native TTR by phagocytosis Preclinical data 1 mabs generated were selective for monomeric, misfolded and amyloidogenic forms of TTR no binding to the native tetramer Immunolabeling of cardiac tissue from patients with ATTR amyloidosis mabs inhibited TTR fibril formation in vitro, and induced antibody-dependent phagocytosis of amyloidogenic TTR A clinical trial of an anti-serum amyloid P component (SAP) monoclonal antibody has been completed in systemic amyloidosis 2
51 Patisiran: Investigational RNAi Therapeutic for hattr Amyloidosis Clinical Development Program Phase 1 1 Phase 2 2 Phase 2 OLE 3 Phase 3 4 APOLLO Global OLE 5 Completed Completed Completed Completed Ongoing Healthy Volunteers hattr hattr hattr hattr Positive results in human healthy volunteers (N=17) Single dose mg/kg by IV infusion Positive multi-dose results in adult patients with hattr amyloidosis (N=29) Multiple doses Multiple schedules Positive results in adult patients with hattr amyloidosis with polyneuropathy who participated in the Phase 2 study (N=27) 0.3 mg/kg every 3 weeks by IV infusion for up to 2 years Adults with hattr amyloidosis with polyneuropathy (N=225) 0.3 mg/kg every 3 weeks by IV infusion for 18 months Randomized, doubleblind, placebocontrolled Adults with hattr amyloidosis with polyneuropathy who participated in the Ph 2 OLE or Ph 3 study (N=211 enrolled) 0.3 mg/kg every 3 weeks by IV infusion Includes some patients with over 3 years treatment Coelho T, et al. N Engl J Med. 2013;369:819-29; 2. Suhr OB, et al. Orphanet J Rare Dis. 2015;10:109; 3. Adams D, et al. Neurology (2017); 88:16 Supplement S (Clinicaltrials.gov: NCT );4. Clinicaltrials.gov: NCT ; 5. Clinicaltrials.gov: NCT
52 Patisiran Phase 3 APOLLO Study Results Enrollment and Disposition Randomized (1:2) (N=225) Placebo (N=77)* Patisiran (N=148)* D/C Treatment (N=29; 37.7%) AE 9.1% Death: 5.2% Progressive disease: 5.2% Physician decision: 2.6% Protocol deviation: 0% Withdrawn by patient 15.6% Study Withdrawal (N=22; 28.6%) D/C Treatment (N=11; 7.4%) AE 2.0% Death: 3.4% Progressive disease: 0.7% Physician decision: 0% Protocol deviation: 0.7% Withdrawn by patient 0.7% Study Withdrawal (N=10; 6.8%) Completed Study (N=55, 71.4%) Completed Study (N=138, 93.2%) 52 *Study populations: modified intent-to-treat (mitt) population: All patients who were randomized and received at least 1 dose of patisiran or placebo (placebo, N=77; patisiran, N=148) Discontinued (d/c) treatment: patients who permanently stopped treatment prior to the last scheduled dose (Week 78 visit); Discontinued (d/c) study: patients who stopped the study before any Month 18 (Week 79-80) assessments were performed Progressive disease: patients who stopped treatment due to rapid disease progression Rapid disease progression: patients who have 24-point increase in mnis+7 from baseline [based on an average of 2 measurements] and FAP Stage progression relative to baseline at 9 months and had no major protocol deviations
53 LS mean (SEM) change in Norfolk QOL-DN from baseline Patisiran Phase 3 APOLLO Study Results Norfolk QOL-DN: Change from Baseline 14.4 (2.73) 7.5 (2.15) Worse 55.5 (8, 111) Difference at 18mos (Pati PBO): p-value: Better 59.6 (5, 119) -7.5 (1.52) -6.7 (1.77) 53 MMRM, mixed-effects model repeated measures; mitt, modified intent to treat; Pati, patisiran; PBO, placebo; CFB, change from baseline Norfolk QOL-DN reference range: -4 to 136
54 Patisiran Phase 3 APOLLO Study Results Additional Secondary Endpoints: Change from Baseline (CFB) to 18 Months All secondary endpoints achieved statistical significance at 18 months Nominal statistical significance was achieved as early as month 9 for NIS-W, R-ODS, 10-MWT and mbmi Secondary endpoint; LS Mean Placebo (N=77) Patisiran (N=148) Treatment Difference (Pati - PBO) P-Value NIS-W R-ODS 10-MWT, m/sec Baseline score, mean CFB to 18 mos Baseline score, mean CFB to 18 mos Baseline score, mean CFB to 18 mos mbmi, kg/m2 x albumin [g/dl] Baseline score, mean CFB to 18 mos COMPASS-31 Baseline score, mean CFB to 18 mos Pati, patisiran; PBO, placebo; NIS-W, neuropathy impairment score-weakness; CFB, change from baseline; R-ODS, Rasch-built Overall Disability Scale; 10-MWT, 10 meter walk test; mbmi, modified body mass index; COMPASS-31, Composite Autonomic Symptom Score questionnaire
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: patisiran_onpattro 11/2018 n/a 5/2019 2/2019 Description of Procedure or Service is a double-stranded small
More informationAPOLLO Phase 3 Study of Patisiran Complete Results
Leo Living with hattr Amyloidosis APOLLO Phase 3 Study of Patisiran Complete Results November 2, 2017 Agenda Welcome Christine Lindenboom Vice President, Investor Relations & Corporate Communications Introduction
More informationThe landscape of ATTR amyloidosis treatment
The landscape of ATTR amyloidosis treatment Teresa Coelho, M.D. Andrade s Center and Neurophysiology Department Hospital Santo António, Centro Hospitalar do Porto Portugal Disclosures Hospital Santo António
More informationSafety and Efficacy of Inotersen in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (NEURO-TTR) Annabel K.
Safety and Efficacy of Inotersen in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (NEURO-TTR) Annabel K. Wang, MD University of California, Irvine ANA 2017 October 17, 2017 San
More informationHereditary ATTR (hattr) Amyloidosis: Polyneuropathy An Overview. Identifying the link can lead to a crucial diagnosis
Hereditary ATTR (hattr) Amyloidosis: Polyneuropathy An Overview Identifying the link can lead to a crucial diagnosis Hereditary ATTR (hattr) Amyloidosis: Polyneuropathy Information about mechanism of disease,
More informationProgress in the Treatment of Cardiac Amyloidosis
Progress in the Treatment of Cardiac Amyloidosis Jignesh Patel MD PhD FACC FRCP Director, Cardiac Amyloid Program Medical Director, Heart Transplant Program Clinical Professor Cedars-Sinai Heart Institute,
More informationEducation Brochure. Hereditary ATTR amyloidosis A closer look at an inherited condition
Education Brochure Hereditary ATTR amyloidosis A closer look at an inherited condition What is hereditary ATTR (hattr) amyloidosis? hattr amyloidosis is caused by a gene change (mutation) that affects
More informationSAFETY AND EFFICACY OF INOTERSEN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY (hattr-pn) Teresa Coelho, MD
SAFETY AND EFFICACY OF INOTERSEN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY (hattr-pn) Teresa Coelho, MD Centro Hospitalar do Porto Porto, Portugal Disclosures Hospital Santo
More informationSubject: Patisiran (Onpattro )
09-J3000-16 Original Effective Date: 12/15/18 Reviewed: 11/14/2018 Revised: 01/01/19 Subject: Patisiran (Onpattro ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF
More informationSilenceurs et inhibiteurs (oligonucléotides antisens) d ARNm dans les neuropathies amyloides héréditaires à transthyrétine : c est parti!
Silenceurs et inhibiteurs (oligonucléotides antisens) d ARNm dans les neuropathies amyloides héréditaires à transthyrétine : c est parti! V. Planté-Bordeneuve Service de Neurologie Réseau Amylose CHU Henri
More informationHereditary ATTR (hattr) Amyloidosis: Cardiomyopathy An Overview. Identifying the link can lead to a crucial diagnosis
Hereditary ATTR (hattr) Amyloidosis: Cardiomyopathy An Overview Identifying the link can lead to a crucial diagnosis Hereditary ATTR (hattr) Amyloidosis: Cardiomyopathy Information about mechanism of disease,
More informationNeuropathy. Nerves before and after TTR. Márcia Waddington Cruz. CEPARM HUCFF-UFRJ.
Neuropathy. Nerves before and after TTR. Márcia Waddington Cruz. CEPARM HUCFF-UFRJ. Amyloidosis Amyloid deposit. Precursor proteins. Fibrilar ptn. Lesion to tissues. Mechanism? 2 A TTR. SSA or Wild Type
More informationSummary of plenary sessions on October 31, 2015
4 th ATTR/Familial Amyloidosis Support Meeting October 31 to November 1, 2015 Hilton Chicago O Hare Airport hotel Summary of plenary sessions on October 31, 2015 1 Contents Welcome... 3 Why are we here?
More informationHereditary ATTR amyloidosis Talking to your healthcare professional about a hereditary condition
Healthcare Professional Discussion Guide Hereditary ATTR amyloidosis Talking to your healthcare professional about a hereditary condition This guide will give you some tips and strategies to help you start
More informationVarun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1
Population Pharmacokinetic (PK) / Pharmacodynamic (PD) Model of Serum Transthyretin (TTR) Following Patisiran Administration in Healthy Volunteers and Patients with Hereditary TTR-Mediated (hattr) Amyloidosis
More informationConference Call to Discuss FDA Approval of ONPATTRO (patisiran)
Conference Call to Discuss FDA Approval of ONPATTRO (patisiran) August 10, 2018 1 Agenda Welcome Christine Lindenboom Vice President, Investor Relations & Corporate Communications Introduction John Maraganore,
More informationXiaoping (Amy) Zhang, Varun Goel, Husain Attarwala, and Gabriel Robbie. Alnylam Pharmaceuticals, Cambridge, USA
Patisiran Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Relationship in Patients with Hereditary Transthyretin-Mediated (hattr) Amyloidosis Xiaoping (Amy) Zhang, Varun Goel,
More informationClinical Profile FOR. Indication. Important Safety Information
Clinical Profile FOR The first and only FDA-approved RNAi treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. 1 Indication ONPATTRO (patisiran) is indicated for
More informationPhase 2 Open-Label Extension Study of Patisiran An RNAi Therapeutic for the Treatment of Familial Amyloidotic Polyneuropathy
Phase 2 Open-Label Extension Study of Patisiran An RNAi Therapeutic for the Treatment of Familial Amyloidotic Polyneuropathy American Neurological Association Annual Meeting October 13, 2014 Agenda Welcome
More informationTTR-FAP: Diagnosis and treatment Zürich June 19,2014. Ole B Suhr Umeå University and University Hospital Department of Medicine Umeå Sweden
TTR-FAP: Diagnosis and treatment Zürich June 19,2014 Ole B Suhr Umeå University and University Hospital Department of Medicine Umeå Sweden Diagnosis of ATTR amyloidosis Clinical symptoms of ATTR- amyloidosis
More informationAmyloid Transthyretin (ATTR) Amyloidosis AN OVERVIEW
Amyloid Transthyretin (ATTR) Amyloidosis AN OVERVIEW AMYLOID TRANSTHYRETIN (ATTR) AMYLOIDOSIS ATTR amyloidosis is a rare, progressive, and fatal disease that manifests clinically with motor and sensory
More information02 November 2017 EU ATTR Meeting Paris
Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy: Results from the Phase 3 APOLLO Study D Adams 1, A Gonzalez-Duarte 2, W O'Riordan 3,
More information04 July 2016 ISA Uppsala, Sweden
Phase 2 Open-Label Extension (OLE) Study of Revusiran An Investigational RNAi Therapeutic for the Treatment of Patients with Transthyretin Amyloidosis with Cardiomyopathy 04 July 2016 ISA Uppsala, Sweden
More informationImpact of Prior TTR Stabilizer Use in Patients with Hereditary Transthyretin-Mediated Amyloidosis in the APOLLO Phase 3 Study of Patisiran
Impact of Prior TTR Stabilizer Use in Patients with Hereditary Transthyretin-Mediated Amyloidosis in the APOLLO Phase 3 Study of T Coelho 1, D Adams 2, A González-Duarte 3, W O Riordan 4, CC Yang 5, T
More informationFamily Tree. Family Health Tree Map your family s history of hereditary ATTR amyloidosis
Family Tree Family Health Tree Map your family s history of hereditary ATTR amyloidosis Chart your family s health history This chart can help you map your family s health history and determine who may
More informationApril 25, 2018 American Academy of Neurology Los Angeles, USA
Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hattr) Amyloidosis with Polyneuropathy Following Treatment with, an Investigational RNAi Therapeutic: Results
More informationApril 24, 2018 American Academy of Neurology Los Angeles, USA
, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hattr) Amyloidosis: Results from the Phase 3 APOLLO Study D Adams 1, A González-Duarte 2, W O'Riordan 3, CC Yang
More informationreversing familial amyloid polyneuropathy naturally the raw vegan plant based detoxification regeneration workbook for healing patients volume 2
DOWNLOAD OR READ : REVERSING FAMILIAL AMYLOID POLYNEUROPATHY NATURALLY THE RAW VEGAN PLANT BASED DETOXIFICATION REGENERATION WORKBOOK FOR HEALING PATIENTS VOLUME 2 PDF EBOOK EPUB MOBI Page 1 Page 2 healing
More information: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis
: A Study Examining the Prevalence of Transthyretin Mutations in Subjects Suspected of Having Cardiac Amyloidosis 02 November 2015 1 Background and Rationale Cardiac amyloidosis is caused by extracellular
More informationCARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD
CARDIAC AMYLOIDOSIS IMAGING ERIC MARTIN MD DISCLOSURES Bayer Dalcor Pharma UK LTD Harvard Clinical Research Institute Heartflow Inc. NIH Vascular Dynamics Employee-Iowa Heart Center/Mercy-Des Moines BACKGROUND
More informationUpdate on Treatments for Systemic Amyloidosis
Update on Treatments for Systemic Amyloidosis Laura M. Dember, M.D. Renal, Electrolyte and Hypertension Division University of Pennsylvania ANZSN Update Course Darwin, Australia September 2, 2017 Disclosure
More informationDiagnosis of Amyloidosis. Maria M. Picken MD, PhD Loyola University Medical Center Chicago
Diagnosis of Amyloidosis Maria M. Picken MD, PhD Loyola University Medical Center Chicago mpicken@lumc.edu 1 Outline Diagnosis of amyloidosis Fat pad Other 2 Amyloidoses protein folding disorders protein
More informationNew approaches in amyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London
New approaches in amyloidosis Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London Systemic Amyloidosis Fatal protein misfolding/aggregation disease caused by accumulation of fibrillar
More informationAmyloidoses are a heterogeneous group of disorders
REPORT Hereditary ATTR Amyloidosis: Burden of Illness and Diagnostic Challenges Morie A. Gertz, MD, MACP Amyloidoses are a heterogeneous group of disorders with a variety of clinical presentations characterized
More informationDaniel Judge presenting on behalf of the AG10 Phase 2 study investigators
Safety, Tolerability and Transthyretin Stabilization by AG10: A Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy and NYHA Class
More informationStage I: Rule-Out Dashboard Secondary Findings in Adults
Stage I: Rule-Out Dashboard GENE/GENE PANEL: DNM2 DISORDER: DNM2-Related Intermediate Charcot-Marie-Tooth Neuropathy HGNC ID: 2974 OMIM ID: 606482 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationA Guide to Transthyretin Amyloidosis
A Guide to Transthyretin Amyloidosis Authored by Teresa Coelho, Bo-Goran Ericzon, Rodney Falk, Donna Grogan, Shu-ichi Ikeda, Mathew Maurer, Violaine Plante-Bordeneuve, Ole Suhr, Pedro Trigo 2016 Edition
More information16 June 2018 European Academy of Neurology Lisbon, Portugal
Outcomes of Patients with Hereditary Transthyretin- Mediated Amyloidosis with Early Onset V30M versus All Other Mutations in APOLLO, a Phase 3 Study of T Coelho 1, D Adams 2, A Gonzalez-Duarte 3, W O Riordan
More informationFrequencies and geographic distributions of genetic mutations in transthyretinand non-transthyretin-related familial amyloidosis
Clin Genet 2015: 88: 396 400 Printed in Singapore. All rights reserved Short Report Frequencies and geographic distributions of genetic mutations in transthyretinand non-transthyretin-related familial
More informationActa Neurologica Belgica Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review
Acta Neurologica Belgica Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review --Manuscript Draft-- Manuscript Number: Full Title: Article Type: Corresponding
More informationCorporate Overview March 2018
Corporate Overview March 2018 1 2018 Alnylam Pharmaceuticals, Inc. Recent News: Strategic Restructuring of Sanofi Alliance Alnylam and Sanofi have restructured alliance to streamline and optimize product
More informationCorporate Overview. January 2018
Corporate Overview January 2018 1 Recent News: Strategic Restructuring of Sanofi Alliance Alnylam and Sanofi have restructured alliance to streamline and optimize product development and commercialization
More informationDiagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
Sekijima et al. Orphanet Journal of Rare Diseases (2018) 13:6 DOI 10.1186/s13023-017-0726-x REVIEW Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters
More informationLate-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan
doi: 10.2169/internalmedicine.1457-18 http://internmed.jp CASE REPORT Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan Zenshi
More informationEidos Therapeutics, Inc.
Eidos Therapeutics, Inc. Precision medicine for transthyretin amyloidosis September 2018 update Eidos forward-looking statements This presentation contains forward-looking statements about Eidos Therapeutics,
More informationCorporate Overview May 2018
Corporate Overview May 2018 1 2018 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities
More informationA Problem with Cardiac Amyloidosis. Defining Amyloidosis. Typical Amyloid Heart. Definition of a double-blind study:
A disease caused by the deposition of a proteinaceous material, derived from the misfolded breakdown products of a normal or abnormal protein. Typical Amyloid Heart Defining Amyloidosis TYPEOF AMYLOID
More information6/6/2017. Uncommon Etiologies of Heart Failure: Cardiac Amyloidosis. Objectives. Case Presentation
Uncommon Etiologies of Heart Failure: Cardiac Amyloidosis Maria Fe White, MSN, FNP/ACNP-BC, FHFSA, CHFN Lead Nurse Practitioner Advance Heart Programs Comprehensive Transplant Center Objectives Describe
More informationRepurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
Research Original Investigation Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial John L. Berk, MD; Ole B. Suhr, MD, PhD; Laura Obici, MD; Yoshiki Sekijima, MD, PhD;
More informationNeurologic Manifestations of Systemic Disease (N Scolding and C Rice, Section Editors)
Curr Treat Options Neurol (2016) 18:53 DOI 10.1007/s11940-016-0436-z Neurologic Manifestations of Systemic Disease (N Scolding and C Rice, Section Editors) Current and Future Treatment Approaches in Transthyretin
More informationESC 2018 Tafamidis Analyst Briefing. August 27, 2018
ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1 Forward Looking Statements This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for
More informationCorporate Overview November 2018
Corporate Overview November 2018 1 2018 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the
More information17 June 2018 European Academy of Neurology Lisbon, Portugal
Impact of Patisiran on Norfolk Quality of Life Questionnaire Diabetic Neuropathy (QOL-DN) in Patients with Hereditary Transthyretin-Mediated Amyloidosis: Results from the Phase 3 APOLLO Study L Obici 1,
More informationLatent Class Analysis to Classify Patients with Transthyretin Amyloidosis by Signs and Symptoms
Neurol Ther (2015) 4:11 24 DOI 10.1007/s40120-015-0028-y ORIGINAL RESEARCH Latent Class Analysis to Classify Patients with Transthyretin Amyloidosis by Signs and Symptoms Jose Alvir. Michelle Stewart.
More informationCorporate Overview August 2018
Corporate Overview August 2018 1 2018 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities
More informationAmyloidosis: Challenges in Diagnosis and Management
Amyloidosis: Challenges in Diagnosis and Management Ronald Witteles, MD Co-Director, Stanford Amyloid Center Associate Professor of Cardiovascular Medicine Program Director, Internal Medicine Residency
More informationDavid Adams 1*, Ole B. Suhr 2, Peter J. Dyck 3, William J. Litchy 3, Raina G. Leahy 4, Jihong Chen 4, Jared Gollob 4 and Teresa Coelho 5
Adams et al. BMC Neurology (2017) 17:181 DOI 10.1186/s12883-017-0948-5 STUDY PROTOCOL Open Access Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with
More informationGuideline of transthyretin-related hereditary amyloidosis for clinicians
Ando et al. Orphanet Journal of Rare Diseases 2013, 8:31 REVIEW Guideline of transthyretin-related hereditary amyloidosis for clinicians Open Access Yukio Ando 1,13*, Teresa Coelho 2, John L Berk 3, Márcia
More informationNEOD001 for amyloid light-chain (AL) amyloidosis
NIHR Innovation Observatory Evidence Briefing: October 2017 NEOD001 for amyloid light-chain (AL) amyloidosis NIHRIO (HSRIC) ID: 10617 NICE ID: 8803 LAY SUMMARY Amyloid light-chain (AL) amyloidosis is caused
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TTR DISORDER: Hereditary transthyretin-related amyloidosis HGNC ID: 12405 OMIM ID: 105210 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as
More informationFourth Quarter and Full Year 2018 Financial Results February 7, 2019
Fourth Quarter and Full Year 2018 Financial Results February 7, 2019 1 2019 Alnylam Pharmaceuticals, Inc. Agenda Welcome Christine Lindenboom Vice President, Investor Relations & Corporate Communications
More informationA Novel Variant Mutation of Transthyretin Ile73Val-Related Amyloidotic Polyneuropathy in Taiwanese
87 A Novel Variant Mutation of Transthyretin Ile73Val-Related Amyloidotic Polyneuropathy in Taiwanese Ming-Feng Liao, Hong-Shiu Chang Abstract- Purpose: Familial amyloidotic polyneuropathy (FAP) is an
More informationAmyloidosis: What to do and how to diagnose: An Update 2017
Amyloidosis: What to do and how to diagnose: An Update 2017 Jonathan L. Kaufman, MD Associate Professor Hematology & Oncology Winship Cancer Institute of Emory University Amyloidosis Protein Conformation/Deposition
More informationFirst Quarter 2018 Financial Results
First Quarter 2018 Financial Results May 3, 2018 1 Agenda Welcome Christine Lindenboom Vice President, Investor Relations & Corporate Communications Q1 2018 Overview John Maraganore, Ph.D. Chief Executive
More informationState of the Art Management of HFpEF
State of the Art Management of HFpEF Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More information12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 28 September 2016
A Randomized, Single-Blind, Placebo-Controlled, Phase /2 Study of ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha- Antitrypsin Deficiency Associated Liver Disease: Interim Study
More informationCorporate Overview March Alnylam Pharmaceuticals, Inc.
Corporate Overview March 2019 1 2019 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements, within the meaning
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Diabetic Neuropathy: A Global and Growing Problem John D. England, MD Louisiana State University Health Sciences Center School of Medicine
More informationAmyloidosis- What does it have to do with Myeloma? Anita D Souza, MD, MS Froedtert & MCW Cancer Center Milwaukee, WI
Amyloidosis- What does it have to do with Myeloma? Anita D Souza, MD, MS Froedtert & MCW Cancer Center Milwaukee, WI Objectives Types of amyloidosis How does amyloidosis form? How is amyloidosis diagnosed?
More informationPrimary Amyloidosis. Kihyun Kim Div. of Hematology/Oncology, Dept. of Medicine, Sungkyunkwan Univ. School of Medidine Samsung Medical Center
Primary Amyloidosis Kihyun Kim Div. of Hematology/Oncology, Dept. of Medicine, Sungkyunkwan Univ. School of Medidine Samsung Medical Center Systemic Amyloidosis A group of complex diseases caused by tissue
More informationFirst Quarter 2017 Financial Results
Colin Living with Porphyria First Quarter 2017 Financial Results May 5, 2017 1 Agenda Welcome Christine Regan Lindenboom Vice President, Investor Relations & Corporate Communications Q1 2017 Overview John
More informationC. Quarta, L. Obici, S. Longhi, S. Perlini, A. Milandri, F. Del Corso, F. Perfetto, F. Cappelli, G. Merlini, C. Rapezzi
Hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: disease profile and differential diagnosis with hypertrophic cardiomyopathy and senile systemic amyloidosis C. Quarta, L.
More informationAmyloidosis and Waldenström s Macroglobulinemia
Amyloidosis and Waldenström s Macroglobulinemia Morie A. Gertz, Giampaolo Merlini, and Steven P. Treon Primary systemic amyloidosis is an immunoglobulin light chain disorder that is 1/5th as common as
More informationMayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather
More informationA celebration of 10 years of THAOS
Newsletter December 17 Transthyretin Amyloidosis Outcomes Survey Spotlight Fabio Barroso Page 2 A celebration of 10 years of THAOS This October saw the third THAOS Investigator meeting, along with the
More informationA Practical Approach to Polyneuropathy SLOCUM DICKSON ANNUAL TEACHING DAY NOVEMBER 4, 2017
A Practical Approach to Polyneuropathy SLOCUM DICKSON ANNUAL TEACHING DAY NOVEMBER 4, 2017 Disclosures Research support from Cytokinetics, Inc Catalyst, Inc Editorial fees from UptoDate. Objectives Describe
More informationDisease specific examination in the diabetic neuropathies. Christopher Gibbons MD, MMSc
Disease specific examination in the diabetic neuropathies Christopher Gibbons MD, MMSc Overview Review the details examination development Review the current status of diabetic neuropathy examinations
More informationReflecting on THAOS in 2016, and looking forward to 2017
Newsletter December 2016 Transthyretin Amyloidosis Outcomes Survey Scientific Board Meeting Summary Page 2 Spotlight Dr Arnt Kristen Page 3 THAOS today Page 4 Recent research from THAOS Page 5 ICON Project
More informationUpdate in Nuclear Imaging of Amyloidosis and Sarcoidosis
Update in Nuclear Imaging of Amyloidosis and Sarcoidosis Balaji Tamarappoo MD, PhD, Cedars-Sinai Heart Institute and Biomedical Imaging Research Institute Cedars-Sinai Medical Center Los Angeles, CA, USA.
More informationEvaluation of Peripheral Neuropathy. Evaluation of Peripheral Neuropathy - Introduction
Evaluation of Peripheral Neuropathy Chris Edwards, MD Ochsner Neurology, Main Campus Evaluation of Peripheral Neuropathy - Introduction A very common complaint in the clinic Presentation is variable Multiple
More informationAmyloidosis. Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London
Amyloidosis Philip Hawkins National Amyloidosis Centre UCL & Royal Free Hospital, London Amyloid Abnormal extracellular fibrillar protein deposit in tissues Pathognomonic red-green birefringence after
More informationInclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia
ORION-1 Trial Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia Lawrence A Leiter, MD, FRCPC, FACP, FACE, FAHA St Michael s Hospital, Toronto 1 Presented on behalf
More informationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
The new england journal of medicine Original Article Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis M.D. Benson, M. Waddington Cruz, J.L. Berk, M. Polydefkis, P.J. Dyck, A.K.
More informationJonathan Katz, MD CPMC
Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC First, a bit of background Classic CIDP--TREATABLE MADSAM/Asymmetric Neuropathy Chronic Length Dependent Neuropathy-
More informationGuide to the use of nerve conduction studies (NCS) & electromyography (EMG) for non-neurologists
Guide to the use of nerve conduction studies (NCS) & electromyography (EMG) for non-neurologists What is NCS/EMG? NCS examines the conduction properties of sensory and motor peripheral nerves. For both
More informationperipheral neuropathy peripheral neuropathy neuropathy peripheral neuropathy neuropathic foot heel Bilateral foot pain Bilateral heel pain bilateral
Peripheral neuropathy (PN) is damage to or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health. The 2018 edition of ICD-10-CM G62.9. Auditory
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare A rare cause of myopathy in adults Jorge Pinheiro MD, José Manuel Lopes MD, PhD Joint Slide Seminar Electron Microscopy and Trainees: Understanding diseases through
More informationIMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY
IMAGING IN CARDIAC AMYLOIDOSIS ; TRENDS IN DIAGNOSIS AND GUIDING THERAPY Mohamed Abo Mandour, MD. Al-Azhar University Cardiac amyloidosis is an under appreciated cause of HF The bottom line pathologic
More informationAmyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation
doi: 10.2169/internalmedicine.8434-16 Intern Med Advance Publication http://internmed.jp CASE REPORT Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a
More informationPhase 1 Trial of ALN-VSP in Cancers Involving the Liver. Annual Meeting of the Controlled Release Society August 2, 2011
Phase 1 Trial of ALN-VSP in Cancers Involving the Liver Annual Meeting of the Controlled Release Society August 2, 2011 Agenda ALN-VSP: Background Phase 1 Trial Study Design Safety Data Tumor Response
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationSelection of Transthyretin Amyloid Inhibitors. Irina Iakovleva
Selection of Transthyretin Amyloid Inhibitors Irina Iakovleva Department of Medical Biochemistry and Biophysics Umeå 2016 Responsible publisher under swedish law: the Dean of the Medical Faculty This work
More informationManagement of Heart Failure in Older Adults
Management of Heart Failure in Older Adults New Data, New Guidelines, New Challenges JOSE NATIVI, MD, MSCI Assistant Professor of Medicine Cardiovascular Director Amyloidosis Program DISCLOSURES - Advisory
More informationThe Internist s Approach to Neuropathy
The Internist s Approach to Neuropathy VOLKAN GRANIT, MD, MSC ASSISTANT PROFESSOR OF NEUROLOGY NEUROMUSCU LAR DIVISION UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE RELEVANT DECLARATIONS Financial disclosures:
More informationDiabetic Neuropathy. Nicholas J. Silvestri, M.D.
Diabetic Neuropathy Nicholas J. Silvestri, M.D. Types of Neuropathies Associated with Diabetes Mellitus p Chronic distal sensorimotor polyneuropathy p Focal compression neuropathies p Autonomic neuropathy
More informationDIABETIC NEUROPATHY ASSESSED AT TWO TIME POINTS FIVE YEARS APART
1 University Department of Neurology, Sarajevo Clinical Center, Sarajevo, Bosnia and Herzegovina 2 Zenica Cantonal Hospital, Zenica, Bosnia and Herzegovina 3 Department of Hemodialysis, Sarajevo Clinical
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationSheena Surindran Grand Rounds 2/15/11
Sheena Surindran Grand Rounds 2/15/11 Affects 5 12 person per million / year 5 10% associated with myeloma Median survival without treatment is 12 40 months Most commonly affected organs are kidney, heart
More information